Trial Profile
Controlled study to investigate management methods of gout attack for gout patients with uric-acid lowering therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Colchicine
- Indications Gout
- Focus Therapeutic Use
- Acronyms FORTUNE-1
- 04 Nov 2017 Primary endpoint (Incidence rate of gout attack during the treatment period) has not been met as per the results published in the Annals of the Rheumatic Diseases
- 04 Nov 2017 Results published in the Annals of the Rheumatic Diseases
- 26 May 2015 Status changed from active, no longer recruiting to completed, according to University Hospital Medical Information Network - Japan record.